뇌 PET-MRI 시스템 시장 : 구성 요소별, 시스템 유형별, 트레이서 유형별, 설치 유형별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Brain PET-MRI Systems Market is projected to grow by USD 802.22 million at a CAGR of 6.32% by 2032.

Hybrid brain PET-MRI systems integrate positron emission tomography with high-field magnetic resonance imaging to capture molecular activity and detailed neuroanatomy in a single session. For neurology, oncology, and psychiatric research, this convergence supports more precise assessment of brain metabolism, perfusion, receptor expression, inflammation, amyloid and tau pathology, tumor recurrence, and treatment response.

Demand is being shaped by the documented rise in dementia, Parkinson's disease, brain tumors, epilepsy, stroke, and therapy-resistant neuropsychiatric disorders. Compared with sequential imaging, simultaneous PET-MRI can improve spatial co-registration, reduce repeat visits, and limit ionizing radiation exposure versus PET-CT because MRI replaces CT for structural imaging. These advantages position brain PET-MRI systems as a premium platform for academic medical centers, translational neuroscience, and complex clinical decision-making.

Transformative Shifts in the Brain PET-MRI Landscape

The brain PET-MRI landscape is shifting from equipment-centric adoption toward integrated neurodiagnostic ecosystems. Hospitals and research centers increasingly evaluate systems based on workflow efficiency, radiotracer compatibility, advanced MRI sequences, quantitative reconstruction, cybersecurity readiness, and interoperability with PACS, RIS, EMR, and research data platforms.

Clinical momentum is closely linked to radiopharmaceutical progress. Regulator-approved amyloid PET tracers and tau PET tracers have strengthened the role of molecular imaging in Alzheimer's disease evaluation, while established FDG-PET remains important for neurodegeneration, epilepsy, and oncology. At the same time, reimbursement variability, high capital costs, radiochemistry infrastructure needs, and shortages of trained technologists remain adoption constraints. Suppliers that combine scanner performance with service models, AI-enabled software, and evidence-generation partnerships are better positioned in this specialized market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative performance multiplier across the brain PET-MRI value chain. In acquisition and reconstruction, AI-based denoising, attenuation correction, motion correction, and image enhancement can support faster protocols and improved quantitative consistency when validated against clinical standards. In interpretation, machine learning assists segmentation, lesion detection, longitudinal comparison, and pattern recognition in dementia, epilepsy, neuro-oncology, and movement disorders.

The impact of AI is strongest when algorithms are trained on diverse, well-curated datasets and embedded into radiologist-controlled workflows. Regulatory oversight, model explainability, bias testing, and post-market monitoring are essential because PET-MRI findings influence high-stakes diagnoses and therapy decisions. Industry leaders should view AI not as a replacement for expert interpretation but as a controlled decision-support layer that improves reproducibility, operational throughput, and research scalability.

Key Regional Insights

North America remains a leading region for brain PET-MRI adoption due to strong academic hospital networks, established neuroimaging research programs, radiopharmaceutical availability, and advanced reimbursement pathways for selected PET indications. The United States drives much of the clinical and translational activity, while Canada contributes through publicly funded neuroscience programs and multi-center research collaborations.

Europe demonstrates broad scientific depth, especially in dementia, neuro-oncology, and radiotracer development, supported by university hospitals, harmonized clinical research practices, and European Union research frameworks. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in advanced diagnostic imaging capacity and aging-population healthcare priorities. Latin America shows selective uptake concentrated in major private and academic centers, particularly where nuclear medicine infrastructure is established. The Middle East is investing in tertiary-care imaging hubs and precision medicine programs, while Africa remains early-stage, with adoption limited by infrastructure, cyclotron access, and specialized workforce constraints, although referral-based neuroimaging demand is gradually increasing in major urban centers.

Key Group Insights

Within ASEAN, demand is concentrated in advanced healthcare systems such as Singapore, Thailand, and Malaysia, where tertiary hospitals, specialist referrals, and medical tourism support premium imaging investment. The GCC is expanding high-end diagnostic capacity through national healthcare transformation programs, making brain PET-MRI relevant for complex neurology, oncology, and precision medicine services.

The European Union benefits from harmonized research funding, cross-border clinical studies, and strong regulatory standards that support evidence-based PET-MRI adoption. BRICS countries present a mixed profile: China and India offer scale and infrastructure expansion, Brazil and South Africa support regional referral hubs, and Russia maintains nuclear medicine expertise despite geopolitical and procurement complexity. G7 markets lead in advanced imaging capacity, reimbursement maturity, and industry-academic partnerships, while NATO countries overlap significantly with high-income markets that prioritize resilience, cybersecurity, and secure medical technology supply chains.

Key Country Insights

The United States leads through academic medical centers, regulated radiotracer innovation, and strong neuro-oncology and dementia research networks. Canada emphasizes publicly funded access and multi-center neuroscience research, while Mexico and Brazil show selective adoption in major metropolitan hospitals with established private and academic imaging services. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain advanced imaging expertise, with Germany and France particularly strong in radiochemistry and university-hospital research; Russia retains nuclear medicine capabilities but faces procurement and collaboration constraints.

In Asia-Pacific, China is scaling advanced hospital infrastructure and domestic imaging capabilities, India is expanding private tertiary-care diagnostics, Japan benefits from an aging population and mature imaging culture, South Korea combines technology adoption with strong hospital systems, and Australia supports neuroimaging through academic and public-health research networks. Country-level opportunity is highest where specialist neurologists, radiologists, nuclear medicine physicians, cyclotron access, reimbursement pathways, and longitudinal care programs align.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical evidence generation, workflow economics, and radiotracer ecosystem partnerships. Demonstrating value requires more than image quality; suppliers and providers must prove reduced diagnostic uncertainty, better longitudinal monitoring, optimized treatment planning, and improved patient throughput in defined indications such as dementia, epilepsy, brain tumors, and complex movement disorders.

Actionable priorities include developing modular service models, strengthening AI governance, improving technologist training, supporting standardized quantitative protocols, and integrating PET-MRI data with enterprise imaging and research platforms. Manufacturers should design upgradeable systems and software-defined capabilities, while providers should build multidisciplinary programs involving radiology, nuclear medicine, neurology, oncology, psychiatry, medical physics, and informatics.

Research Methodology

This executive summary is built on a secondary-research framework using publicly available and verifiable sources, including regulatory agency information, clinical imaging guidelines, peer-reviewed literature, hospital adoption patterns, radiopharmaceutical approvals, health-technology assessment principles, and macro healthcare infrastructure indicators. The analysis emphasizes confirmed market drivers rather than speculative claims.

Insights were synthesized through triangulation across technology trends, clinical use cases, regional healthcare capacity, reimbursement considerations, and radiotracer availability. Qualitative assessment was applied to evaluate adoption readiness by region, group, and country, with attention to advanced imaging infrastructure, nuclear medicine capability, specialist workforce, research intensity, and policy environment.

Conclusion

Brain PET-MRI systems occupy a specialized but strategically important segment of advanced neuroimaging. Their value lies in combining molecular PET biomarkers with high-resolution MRI in a single platform, enabling deeper insight into neurodegeneration, neuro-oncology, epilepsy, and emerging precision-neurology applications.

The market will be shaped by radiopharmaceutical innovation, AI-enabled workflow improvements, reimbursement evidence, and regional infrastructure maturity. Organizations that align clinical validation, operational efficiency, data interoperability, and multidisciplinary expertise will be best positioned to capture long-term value in the brain PET-MRI systems market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain PET-MRI Systems Market, by Component

• 7.1. Hardware
  • 7.1.1. PET Detector
  • 7.1.2. MRI Magnet
  • 7.1.3. RF Coils
• 7.2. Software
  • 7.2.1. Image Reconstruction
  • 7.2.2. Motion Correction
  • 7.2.3. Attenuation Correction
  • 7.2.4. Fusion & Visualization
• 7.3. Services
  • 7.3.1. Installation & Calibration
  • 7.3.2. Maintenance & Repair
  • 7.3.3. Training & Support

8. Brain PET-MRI Systems Market, by System Type

• 8.1. Simultaneous PET-MRI Systems
• 8.2. Sequential PET-MRI Systems

9. Brain PET-MRI Systems Market, by Tracer Type

• 9.1. Metabolic Tracers
• 9.2. Amyloid Tracers
• 9.3. Tau Tracers
• 9.4. Dopaminergic Tracers
• 9.5. Neuroinflammation Tracers

10. Brain PET-MRI Systems Market, by Installation Type

• 10.1. New Installations
• 10.2. Replacement/Upgrade

11. Brain PET-MRI Systems Market, by Application

• 11.1. Neurodegenerative Diseases
  • 11.1.1. Alzheimer's Disease
  • 11.1.2. Parkinson's Disease
  • 11.1.3. Huntington's Disease
• 11.2. Brain Tumors
• 11.3. Epilepsy
• 11.4. Cerebrovascular Diseases
• 11.5. Psychiatric & Neurodevelopmental Disorders
• 11.6. Traumatic Brain Injury
• 11.7. Research & Drug Development

12. Brain PET-MRI Systems Market, by End User

• 12.1. Diagnostic Centers
• 12.2. Hospitals
• 12.3. Research Institutions
• 12.4. Academic & Research Institutes
• 12.5. Ambulatory Surgical Centers

13. Brain PET-MRI Systems Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Brain PET-MRI Systems Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Brain PET-MRI Systems Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aspect Imaging Ltd.
• 17.2. Bruker Corporation
• 17.3. Canon Medical Systems Corporation
• 17.4. Cubresa Inc.
• 17.5. Esaote SpA
• 17.6. Fonar Corporation
• 17.7. GE Healthcare
• 17.8. Hamamatsu Photonics K.K.
• 17.9. Hitachi Ltd.
• 17.10. inviscan SAS
• 17.11. Koninklijke Philips N.V.
• 17.12. Mediso Ltd.
• 17.13. MR Solutions Ltd.
• 17.14. Neusoft Medical Systems Co. Ltd.
• 17.15. Positrigo AG
• 17.16. Shanghai United Imaging Healthcare Co., Ltd.
• 17.17. Shimadzu Corporation
• 17.18. Siemens Healthineers AG